OXIS IS HOT!!!
Post# of 325
Posted On: 09/13/2015 11:29:42 PM
With the new SEC filing and license this stock is on the radar. Share prices such to be on the rise. We should see a PR from the New York conference September 10 th yet as well.
Take a look at the article and statements made moving OXIS forward from present to 2018:
"A diverse spectrum of novel agents have shown therapeutic potential in myeloma clinic, however high relapse rates and drug resistance continue to plague these therapies due to blurred multiple myeloma pathogenesis. Thus, novel targets and treatment in multiple myeloma pathogenesis are of critical importance to improve the patient outcomes. The 2010 launched anti-multiple myeloma drug Valcade became a top 10 best-selling anti-cancer drug. Approximately, 30% to 50% of patients with multiple myeloma do not respond to the first-line therapy. According to the Decision Resources Report, the multiple myeloma drug markets will grow more than double from $2.1 billion to $5.3 billion in 2018.
(http://decisionresources.com/News-and-Events/Press-Releases/Multiple-Myeloma-032210).
"Our focus for 2015 is to continue to make significant progress with Oxis Biotech, Inc by adding additional high value patent and assets to its portfolio over the very near future. Further adding value and strength to the market capitalization of Oxis. These opportunities for Oxis will add accelerated pathways for several of our current indications as we advance these assets towards FDA approval. We also plan to take advantage of the new regulatory pathways in Europe with our Oxis Biotech product offerings. The new laws in Europe (Adaptive Licensing) now allows for limited commercialization after a successful Phase 2 trial for indications that meet defined criteria. We hope to position Oxis Biotech to take advantage of this new opportunity, which should attract potential strategic partners for our unique platform.
We see great opportunities to continue to build our company in 2015. These opportunities are based on a foundation of great science and technologies, focusing on advancing the development of effective small molecule drugs that may enable better quality of life for patients, and an organization wholly committed to working towards its goals and effectively responding to the deficiency issues of approved drugs in multi billion dollar therapy markets that our products are well suited for, giving Oxis great economic prospects for success.
I am excited about what the future holds for Oxis and it stockholders as we attain our goals for 2015. I have employed the same strategy that I used as founder of Lion Biotechnologies for Oxis Biotech, Inc. Our strategy is sound and our organization is aligned to execute our mission to enable us to develop products for patients in need, while continuing to build our business and become a leader in our industry. Oxis will continue to focus our efforts on solid science with real data. We also understand how important it is to articulate our efforts to our stockholders by providing meaningful information in a timely fashion. Thank you so much for your commitment to Oxis International, Inc. and Oxis Biotech, Inc.
Sincerely,
Tony Cataldo
Chairman and Chief Executive Officer
http://www.prnewswire.com/news-releases/oxis-...40314.html
This is not the newest news but contains information that includes plans that have been implemented and future plans up to 2018.
Take a look at the article and statements made moving OXIS forward from present to 2018:
"A diverse spectrum of novel agents have shown therapeutic potential in myeloma clinic, however high relapse rates and drug resistance continue to plague these therapies due to blurred multiple myeloma pathogenesis. Thus, novel targets and treatment in multiple myeloma pathogenesis are of critical importance to improve the patient outcomes. The 2010 launched anti-multiple myeloma drug Valcade became a top 10 best-selling anti-cancer drug. Approximately, 30% to 50% of patients with multiple myeloma do not respond to the first-line therapy. According to the Decision Resources Report, the multiple myeloma drug markets will grow more than double from $2.1 billion to $5.3 billion in 2018.
(http://decisionresources.com/News-and-Events/Press-Releases/Multiple-Myeloma-032210).
"Our focus for 2015 is to continue to make significant progress with Oxis Biotech, Inc by adding additional high value patent and assets to its portfolio over the very near future. Further adding value and strength to the market capitalization of Oxis. These opportunities for Oxis will add accelerated pathways for several of our current indications as we advance these assets towards FDA approval. We also plan to take advantage of the new regulatory pathways in Europe with our Oxis Biotech product offerings. The new laws in Europe (Adaptive Licensing) now allows for limited commercialization after a successful Phase 2 trial for indications that meet defined criteria. We hope to position Oxis Biotech to take advantage of this new opportunity, which should attract potential strategic partners for our unique platform.
We see great opportunities to continue to build our company in 2015. These opportunities are based on a foundation of great science and technologies, focusing on advancing the development of effective small molecule drugs that may enable better quality of life for patients, and an organization wholly committed to working towards its goals and effectively responding to the deficiency issues of approved drugs in multi billion dollar therapy markets that our products are well suited for, giving Oxis great economic prospects for success.
I am excited about what the future holds for Oxis and it stockholders as we attain our goals for 2015. I have employed the same strategy that I used as founder of Lion Biotechnologies for Oxis Biotech, Inc. Our strategy is sound and our organization is aligned to execute our mission to enable us to develop products for patients in need, while continuing to build our business and become a leader in our industry. Oxis will continue to focus our efforts on solid science with real data. We also understand how important it is to articulate our efforts to our stockholders by providing meaningful information in a timely fashion. Thank you so much for your commitment to Oxis International, Inc. and Oxis Biotech, Inc.
Sincerely,
Tony Cataldo
Chairman and Chief Executive Officer
http://www.prnewswire.com/news-releases/oxis-...40314.html
This is not the newest news but contains information that includes plans that have been implemented and future plans up to 2018.
(0)
(0)